Germany's RAG Foundation could sell entire Evonik stake

RAG Foundation said it can sell up to its entire 43% stake in German chemicals maker Evonik, subject to approval by its board of trustees. RAG had previously planned to reduce its holding only to a 25.1% blocking minority. The disclosure raises the prospect of a change in control or strategic transaction, particularly after competitor BASF recently sought to acquire Evonik.

Analysis

The key valuation change is not simply takeover optionality; it is the removal of a permanent-control-shareholder discount. A large strategic block can either be placed at a discount, creating near-term technical pressure, or transferred with control protections that force a full-company bid. EVK’s downside therefore depends on process design: a marketed secondary could clear 5-10% below spot within days, while an agreed strategic transaction could justify a materially larger control premium over 1-3 months.

BASF is a credible industrial buyer but not necessarily the highest-value bidder. Its own portfolio simplification, weak European chemicals backdrop and balance-sheet constraints make a cash-heavy bid difficult to underwrite without asset sales or meaningful synergies; regulatory remedies in overlapping specialty segments could also dilute deal economics. A politically influenced seller may prioritize German employment and governance commitments, which improves BASF’s strategic position versus financial sponsors but raises execution risk and lengthens any review timeline.

The contrarian view is that EVK may already trade too much on an imminent-bid narrative. Specialty chemicals M&A multiples have been constrained by uncertain European industrial demand and elevated financing costs; absent a formal process, the more probable near-term event is block-placement speculation rather than a signed offer. Over 6-18 months, however, a more diversified shareholder base could pressure EVK toward sharper portfolio actions, capital-return discipline, or separations—potentially supporting the standalone multiple even if BASF does not transact.

Key Decisions for Investors

• Maintain a tactical long EVK.DE only on confirmation of a formal sale process or strategic-buyer engagement; target a 10-15% premium outcome over 1-3 months, but use a 7% stop because a discounted accelerated placement is the most immediate adverse scenario.
• Prefer a hedged event position: long EVK.DE / short BAS.DE in beta-neutral sizing after verified process initiation. EVK captures control-premium optionality while BASF bears financing, remedy and integration-risk if it becomes the buyer; reassess if BASF explicitly rules itself out or EVK’s spread widens without transaction disclosure.
• Do not treat BASF as a standalone long on this development. A BASF bid would likely be viewed initially as capital-allocation negative unless management identifies funded disposals and quantifies synergies sufficient to offset a control premium; watch for leverage guidance and asset-sale commitments before positioning.
• Set an alert for any disclosed block-sale structure, lock-up terms, or competing-bidder language. A placement below market without control rights would invalidate the near-term M&A thesis and favor reducing EVK exposure; a transaction granting governance rights or requiring a mandatory offer would justify adding.